The purpose of this study is to evaluate the safety and effectiveness of a new combination therapy for the treatment of dogs with meningioma. This combination consists of oral hydroxyurea, a conventional chemotherapy drug used to treat brain tumors, and PAC-1, a new chemotherapy drug which has been shown to selectively kill cancer cells in recent clinical trials. This combination has not been evaluated in dogs with meningioma before.
Dogs will be randomly assigned to receive either hydroxyurea or PAC-1 for seven days, after which all dogs will receive both medications orally.
Dogs enrolled in this clinical trial will have six visits to Penn Vet as well as three overnight visits to the National Institutes of Health in Bethesda, MD. All of these visits are required for study participation. At the final study visit dogs will have surgery at Penn Vet to remove the brain tumor.
- Diagnosis via MRI of a meningioma (type of brain tumor) amenable to surgical removal
- No history of adverse events under anesthesia/sedation
- No history of radiation therapy or chemotherapy for meningioma
All study medication, blood work, imaging, and study visits are covered by the study. The study also provides up to $2000 credit toward the cost of surgical removal at the end of the study.